First AD

Second AD

ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL 

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Insights Video Series

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Transforming Large B-Cell Lymphoma (LBCL): CAR T and Novel Agents

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

Understanding LBCL: Presentation, Diagnosis, and Prognostic Indicators

Large B-Cell Lymphoma: Treatment Approaches and Evolving Therapies

Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies

CAR T-Cell Therapy’s Impact on Lymphoma Management

Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

Challenges in CAR T-Cell Therapy for Lymphoma

Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma

Approaches to Treatment Sequencing in LBCL

Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics

Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL  

Observations in Progression Post-CAR T for Lymphoma

Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

Future Perspectives in Large B-Cell Lymphoma